Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19
MNI is dedicated to developing and offering phytochemical (plant-based) products and healthcare solutions, aimed at treating metabolic syndrome
The company will also share results in two additional posters for deuruxolitinib
MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
Phase 3 clinical trial designed to evaluate the safety and efficacy of tivozanib in combination with nivolumab
ForDoz Pharma Corporation, USA (ForDoz) received an approval for its ANDA from the USFDA
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
Phase 3 study results will form the basis for future discussions with global regulatory authorities
Subscribe To Our Newsletter & Stay Updated
